Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

PHASE3CompletedINTERVENTIONAL
Enrollment

1,146

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Prophylaxis of Ross River Virus Infection
Interventions
BIOLOGICAL

Ross River Virus (RRV) Vaccine

Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.

Trial Locations (13)

2010

Holdsworth House Medical Practice, Darlinghurst

St. Vincent´s Hospital, Darlinghurst

2145

National Centre for Immunisation Research & Surveillance, The Children´s Hospital Westmead, Westmead

3084

Centre for Clinical Studies, Heidelberg

3145

Emeritus Research, Malvern East

3220

Barwon Health - The Geelong Hospital, Dept Clinical & Biomedical Sciencesl, Geelong

4029

QPID Clinical Trials Centre, Royal Children´s Hospital, Herston

4066

Wesley Research Institute Clinical Trials Centre, The Wesley Hospital, Auchenflower

4870

Cairns Base Hospital, Cairns

5006

CMAX, a Division of the Institute of Drug Technology (IDT) Australia, Ltd., North Adelaide

5042

Dept of Microbiology & Infectious Diseases, Bedford Park

6009

Linear Clinical Research, Nedlands

6840

Princess Margaret Hospital for Children, Perth

All Listed Sponsors
lead

Alachua Government Services, Inc.

INDUSTRY

NCT01604746 - Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 | Biotech Hunter | Biotech Hunter